1.Dosimetric comparison in 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy with 5-field for thoracic middle esophageal carcinoma
Shouguo LI ; Qingluo ZHANG ; Jianguo FU ; Pengxing LI ; Rurong HOU
Cancer Research and Clinic 2011;23(11):752-755
Objective To compare the difference of dosimetric results between 3-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) with 5-field for thoracic middle esophageal carcinoma.Methods Ten patients with thoracic middle esophageal carcinoma were involved in this study.Four treatment plans were designed for each patient,including one 3D-CRT plan and three IMRT plans with 5-field and all evaluation contents were compared.Results There were no significant differences of cord Dmax,total-lung mean dose (Dmean),L-lung Dmean and R-lung V25,V30.Significant differences of heart V30,V40 and Dmean were obtained among the plans,with the lowest of 5IMRT2 (V30:28.67±15.97,V40:13.04±7.28,Dmean:2097.76±718.26) and 5IM RT3(27.39±14.96,13.00±7.32,2096.16±718.85),the highest of 5CRT (43.27±18.69,26.83±19.18,2393.48±896.12) and 5IMRT1 (41.81±17.16,23.08±11.17,2403.77±834.73).There were significant differences of L-lung V5,V10,V15,V20 V25 and V30.All IMRT plans reduce V20,V25 and V30.5IMRT1 did not increase V5 (54.39±7.58) and V10 (44.76±6.30),but reducesd V15 (20.86±5.16),5IMRT2 (V5:70.89±7.95,V10:50.94±8.71,V15:34.20±6.62) and 5IMRT3 (V5:70.26±7.94,V10:49.80±7.62,V15:34.60±5.40)increased V5,V10 and V15.There were also significant differences of R-lung V5.V10,V10,V20 and Dmean.All IMRT plans reduced V20,but increased Vs and V10.5IMRT1 did not increase V15 (23.67±5.73) and Dmean (923.49±182.34); 5IMRT2 did not increases V15 (26.72±±6.79) but increases Dmean (1060.34±205.02); 5IMRT3 increased both V15 (32.40±6.59) and Dmean (1100.54±197.84).Significant differences were found in Dmean,homogeneity index (HI) and conformity index (CI) of PTV,with the best Dmean of 5IMRT1 (6219.80±37.90),the second of 5IMRT3 (6268.91±56.26); the best HI of 5IMRT1 (0.0870±0.0219) and 5IMRT3 (0.0990±0.0219);the best CI of 5IRT2 (0.8682±0.0172) and 5IMRT3 (0.8667±0.0183).Conclusion 5-field IMRT plans have the advantages in the treatment of thoracic middle esophageal carcinoma with better HI,CI of target volume and sparing of lung (V20,V25 and V30) compared to 3D-CRT.5IMRT1 plan has the advantages in reducing low-dose volume (V5,V10,V15 and Dmean) of lung.
2.Effect of Intensive Training and on Motor Function of Cerebral Infarction Patients
Yanzhen BI ; Zhixiong ZHENG ; Kangzeng LI ; Pengxing LIN
Chinese Journal of Rehabilitation Theory and Practice 2009;15(7):664-665
Objective To investigate the effects of intensive training and on the activity of daily living (ADL) and motor function in cerebral infarction patients. Methods 52 cerebral infarction patients with early rehabilitation were divided into an experiment group (n=26) and a control group (n=26). All patients were treated with the conventional training. Meanwhile, the patients in the experimental group were also treated with intensive training. The Modified Barthels Index (MBI) and brief-style Fugl-Meyer assessment (FMA) were used to evaluate the ADL and motor function before and 1 month after treatment. Results The scores of MBI and FMA were significantly different between the two groups 1 month after treatment (P<0.05). Conclusion Intensive training can improve the ADL and motor function more than conventional training in cerebral infarction patients.
3.Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing.
Zhiru WANG ; Wenting KANG ; Ouwen LI ; Fengyu QI ; Junwei WANG ; Yinghua YOU ; Pengxing HE ; Zhenhe SUO ; Yichao ZHENG ; Hong-Min LIU
Acta Pharmaceutica Sinica B 2021;11(3):694-707
Targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved for treating melanoma, gastric cancer (GC) and bladder cancer with clinical benefit. Nevertheless, many patients failed to respond to anti-PD-1/PD-L1 treatment, so it is necessary to seek an alternative strategy for traditional PD-1/PD-L1 targeting immunotherapy. Here with the data from The Cancer Genome Atlas (TCGA) and our in-house tissue library, PD-L1 expression was found to be positively correlated with the expression of ubiquitin-specific processing protease 7 (USP7) in GC. Furthermore, USP7 directly interacted with PD-L1 in order to stabilize it, while abrogation of USP7 attenuated PD-L1/PD-1 interaction and sensitized cancer cells to T cell killing